CA-SCIENTIST.COM
15.12.2020 13:57:10 CET | Business Wire | Press release
Scientist.com, the healthcare industry’s leading marketplace for outsourced R&D, announced today it will acquire HealthEconomics.Com, a private US-based company that has spent the last 25 years creating a global Connected Community™ of scientists and suppliers of health economics and outcomes research (HEOR), real world evidence (RWE) and market access services. The acquisition, expected to be completed in January, reflects Scientist.com’s mission to empower and connect scientists worldwide and HealthEconomics.Com’s mission to create a connected global community focused on improving patient outcomes.
“The healthcare and pharmaceutical industries are increasingly using value-based approaches to evaluate new and existing therapies; Patti and her team at HealthEconomics.Com are the pioneers of this fast-growing area," stated Kevin Lustig, PhD, CEO and founder of Scientist.com. “Combining our two platforms helps researchers evaluate and purchase critical HEOR and RWE solutions needed to improve patient access to high quality, cost-effective medicines.”
HealthEconomics.Com was founded in 1994 as a resource portal for researchers, payers and academics engaged in generating or evaluating data and evidence to describe the clinical, economic and patient-reported outcomes of healthcare interventions. It has expanded to global prominence among the ever-growing community of stakeholders by facilitating important industry connections between researchers and solution providers, and through its central repository of current news, resources, jobs, events and educational assets.
“It has become clear over the past 25 years that HEOR and RWE are critical tools in healthcare research. This has resulted in a huge increase in the number of medical researchers, payers and providers using HEOR and RWE to improve value-based decision-making,” remarked Dr. Patti Peeples, RPh, PhD, CEO and founder of HealthEconomics.Com. “Joining forces with Scientist.com enables us to accelerate the adoption of best practices by researchers and service providers across this fast-growing community.”
For more information or to register as a buyer or seller, visit http://www.scientist.com/rwe-heor
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk, and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies, the Biotechnology Innovation Organization (BIO), and the US National Institutes of Health (NIH).
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005109/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Launches Cash Tender Offer28.9.2026 13:21:00 CEST | Press release
THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE MARKET ABUSE REGULATION (EU) 596/2014. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT)) OR IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (SEE “OFFER AND DISTRIBUTION RESTRICTIONS” BELOW). SES (the “Offeror”) announces today that it is inviting holders of its outstanding €500,000,000 0.875 per cent. Guaranteed Notes
Horizon3 Earns Cyber Essentials Certification Covering NodeZero EU Network28.9.2026 10:00:00 CEST | Press release
Certification provides a defined security baseline for the network supporting Horizon3’s EU data sovereignty site in Germany Horizon3, the AI-Native Proactive Security Company, today announced that it has earned Cyber Essentials Plus certification covering its NodeZero AWS EU network. The network supports Horizon3’s EU data sovereignty site in Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928143792/en/ Horizon3 Earns Cyber Essentials Certification Covering NodeZero EU Network Organizations use NodeZero® to test production environments and find weaknesses attackers can exploit. When customers and partners assess the platform itself, they also need to understand the security standards applied to its supporting infrastructure. The Cyber Essentials certificate identifies a defined portion of that infrastructure and the baseline against which it was assessed. Developed by the UK’s National Cyber Security Centre, Cybe
Thales Expands Collaboration with Google Cloud to Help Secure Agentic AI Workflows28.9.2026 09:03:00 CEST | Press release
Integration enables new protections for communications between AI agents, models, enterprise data, and tools to help control what agents can access, share, and do Thales AI Security Fabric mitigates risks, brings enhanced visibility and policy enforcement to AI-driven workflows on Google Cloud Thales today announced an expanded collaboration with Google Cloud to help enterprises address emerging security and governance challenges associated with agentic AI, bringing integrated protection, visibility, and policy enforcement to AI-driven workflows on Google Cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928647188/en/ ©Thales The integration of Thales AI Security Fabric with Google Cloud Gemini Enterprise helps organizations apply security, governance, and visibility across interactions among users, agents, models, and tools in real time. “Enterprises are moving from AI assistants to AI agents that can autonomously ta
SPORVIGILANCE Targets Safer Medicines and Billion-Euro Savings for Global Pharma Facing EU IDMP Fines28.9.2026 08:13:00 CEST | Press release
British regulatory technology company SPORVIGILANCE is targeting one of global pharma’s major compliance challenges with a platform offering a faster route to IDMP and SPOR readiness, compliance and governance. As the European Medicines Agency advances structured medicinal product data, companies face pressure to keep regulatory data accurate, standardised and aligned with EMA requirements. SPORVIGILANCE replaces fragmented manual assessment with a regulatory intelligence layer built around IDMP, SPOR and Product Management Service (PMS) requirements. At its core is an IDMP Business Rule Validation Engine that assesses medicinal product data at scale and at field level, identifying missing, inconsistent and non-compliant data. SPORVIGILANCE is the only platform to translate IDMP business rules directly into automated validation logic, enabling companies to test data against the rules rather than rely on manual interpretation. Its PMS Alignment capability reconciles internal RIM data ag
Sofinnova Partners Closes Oversubscribed €82 Million Sofinnova MD Start IV Fund to Create the Next Generation of Medtech Companies28.9.2026 08:00:00 CEST | Press release
The new fund extends Sofinnova’s 20-year track record of company creation with capacity to launch six to eight new ventures across Europe and the US Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova MD Start IV at €82 million. The fund, which was oversubscribed, will help expand Sofinnova's medtech company-creation strategy across Europe and the US with greater capacity to launch new ventures and support them through key stages of development. With plans to launch six to eight new medtech companies over the next five years, Sofinnova MD Start IV will support ventures from inception through key clinical and operational milestones, providing founders with both capital and hands-on support. Sofinnova MD Start's approach combines clinical insight, entrepreneurial talent, and operational expertise to tackle significant unmet medical needs. The previous fund, Sofinnova MD Sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom